Synthesized peptide derived from human PIK3CA H1047R AA range: 1000-1068

The antibody can specifically recognize the h1047r mutation of human PIK3CA protein, and does not react with wild-type PIK3CA protein.

PIK3CA

5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha;5-bisphosphate 3-kinase catalytic subunit alpha isoform;caPI3K;CLOVE;CWS5;MCAP;MCM;MCMTC;MGC142161;MGC142163;p110 alpha;p110alpha;Phosphatidylinositol 3 kinase catalytic alpha polypeptide;Phosphatidylinositol 3 kinase catalytic 110 KD alpha;Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha;Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform;Phosphatidylinositol 4,5 bisphosphate 3 kinase 110 kDa catalytic subunit alpha;Phosphatidylinositol-4;Phosphoinositide 3 kinase catalytic alpha polypeptide;PI 3 Kinase catalytic subunit alpha;PI3 kinase p110 subunit alpha;PI3-kinase subunit alpha;PI3K;PI3K-alpha;PI3KC A;PIK3C A;Pik3ca;PK3CA;PK3CA_HUMAN;PtdIns 3 kinase p110;PtdIns-3-kinase subunit alpha;PtdIns-3-kinase subunit p110-alpha;Serine/threonine protein kinase PIK3CA

5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha ;
5-bisphosphate 3-kinase catalytic subunit alpha isoform ;
caPI3K ;
CLOVE ;
CWS5 ;
MCAP ;
MCM ;
MCMTC ;
MGC142161 ;
MGC142163 ;
p110 alpha ;
p110alpha ;
Phosphatidylinositol 3 kinase catalytic alpha polypeptide ;
Phosphatidylinositol 3 kinase catalytic 110 KD alpha ;
Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha ;
Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform ;
Phosphatidylinositol 4,5 bisphosphate 3 kinase 110 kDa catalytic subunit alpha ;
Phosphatidylinositol-4 ;
Phosphoinositide 3 kinase catalytic alpha polypeptide ;
PI 3 Kinase catalytic subunit alpha ;
PI3 kinase p110 subunit alpha ;
PI3-kinase subunit alpha ;
PI3K ;
PI3K-alpha ;
PI3KC A ;
PIK3C A ;
Pik3ca ;
PK3CA ;
PK3CA_HUMAN ;
PtdIns 3 kinase p110 ;
PtdIns-3-kinase subunit alpha ;
PtdIns-3-kinase subunit p110-alpha ;
Serine/threonine protein kinase PIK3CA

Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit , which uses ATP to phosphorylate PtdIns , PtdIns4P and PtdIns (4 ,5) P2. This gene has been found to be oncogenic and has been implicated in cervical cancers. A pseudogene of this gene has been defined on chromosome 22. [provided by RefSeq , Apr 2016] ,

Catalytic activity:ATP + 1-phosphatidyl-1D-myo-inositol 4 ,5-bisphosphate = ADP + 1-phosphatidyl-1D-myo-inositol 3 ,4 ,5-trisphosphate. ,Disease:Defects in PIK3CA are associated with breast cancer [MIM:114480]. ,Disease:Defects in PIK3CA are associated with colorectal cancer (CRC) [MIM:114500]. ,Disease:Defects in PIK3CA are associated with ovarian cancer [MIM:167000]. Ovarian cancer is the leading cause of death from gynecologic malignancy. It is characterized by advanced presentation with loco-regional dissemination in the peritoneal cavity and the rare incidence of visceral metastases. These typical features relate to the biology of the disease , which is a principal determinant of outcome. ,Disease:Defects in PIK3CA may underlie hepatocellular carcinoma (HCC) [MIM:114550]. ,Disease:PI3KCA mutations affecting exons 9 and 20 display gender-and tissue-specific patterns , thus suggesting that the different amino acid changes could exert distinct functional effects on the oncogenic properties of this enzyme. Furthermore , sexual dimorphisms and tissue specific factors might directly or indirectly influence the occurrence of PI3KCA cancer alleles. ,Function:Phosphorylates PtdIns , PtdIns4P and PtdIns (4 ,5) P2 with a preference for PtdIns (4 ,5) P2. ,similarity:Belongs to the PI3/PI4-kinase family. ,similarity:Contains 1 C2 domain. ,similarity:Contains 1 PI3K/PI4K domain. ,subunit:Heterodimer of a p110 (catalytic) and a p85 (regulatory) subunit. Binds to IRS1 in nuclear extracts. Interacts with RUFY3. ,

Cytoplasmic

>>Inositol phosphate metabolism ;
>>Metabolic pathways ;
>>EGFR tyrosine kinase inhibitor resistance ;
>>Endocrine resistance ;
>>Platinum drug resistance ;
>>ErbB signaling pathway ;
>>Ras signaling pathway ;
>>Rap1 signaling pathway ;
>>cAMP signaling pathway ;
>>Chemokine signaling pathway ;
>>HIF-1 signaling pathway ;
>>FoxO signaling pathway ;
>>Phosphatidylinositol signaling system ;
>>Sphingolipid signaling pathway ;
>>Phospholipase D signaling pathway ;
>>Autophagy - animal ;
>>mTOR signaling pathway ;
>>PI3K-Akt signaling pathway ;
>>AMPK signaling pathway ;
>>Apoptosis ;
>>Longevity regulating pathway ;
>>Longevity regulating pathway - multiple species ;
>>Cellular senescence ;
>>Axon guidance ;
>>VEGF signaling pathway ;
>>Osteoclast differentiation ;
>>Focal adhesion ;
>>Signaling pathways regulating pluripotency of stem cells ;
>>Platelet activation ;
>>Neutrophil extracellular trap formation ;
>>Toll-like receptor signaling pathway ;
>>C-type lectin receptor signaling pathway ;
>>JAK-STAT signaling pathway ;
>>Natural killer cell mediated cytotoxicity ;
>>T cell receptor signaling pathway ;
>>B cell receptor signaling pathway ;
>>Fc epsilon RI signaling pathway ;
>>Fc gamma R-mediated phagocytosis ;
>>TNF signaling pathway ;
>>Leukocyte transendothelial migration ;
>>Neurotrophin signaling pathway ;
>>Cholinergic synapse ;
>>Inflammatory mediator regulation of TRP channels ;
>>Regulation of actin cytoskeleton ;
>>Insulin signaling pathway ;
>>Progesterone-mediated oocyte maturation ;
>>Estrogen signaling pathway ;
>>Prolactin signaling pathway ;
>>Thyroid hormone signaling pathway ;
>>Regulation of lipolysis in adipocytes ;
>>Relaxin signaling pathway ;
>>GnRH secretion ;
>>Type II diabetes mellitus ;
>>Insulin resistance ;
>>Non-alcoholic fatty liver disease ;
>>AGE-RAGE signaling pathway in diabetic complications ;
>>Growth hormone synthesis , secretion and action ;
>>Aldosterone-regulated sodium reabsorption ;
>>Carbohydrate digestion and absorption ;
>>Alzheimer disease ;
>>Spinocerebellar ataxia ;
>>Prion disease ;
>>Bacterial invasion of epithelial cells ;
>>Shigellosis ;
>>Salmonella infection ;
>>Yersinia infection ;
>>Chagas disease ;
>>Amoebiasis ;
>>Hepatitis C ;
>>Hepatitis B ;
>>Measles ;
>>Human cytomegalovirus infection ;
>>Influenza A ;
>>Human papillomavirus infection ;
>>Human T-cell leukemia virus 1 infection ;
>>Kaposi sarcoma-associated herpesvirus infection ;
>>Herpes simplex virus 1 infection ;
>>Epstein-Barr virus infection ;
>>Human immunodeficiency virus 1 infection ;
>>Coronavirus disease - COVID-19 ;
>>Pathways in cancer ;
>>Viral carcinogenesis ;
>>Proteoglycans in cancer ;
>>MicroRNAs in cancer ;
>>Chemical carcinogenesis - receptor activation ;
>>Chemical carcinogenesis - reactive oxygen species ;
>>Colorectal cancer ;
>>Renal cell carcinoma ;
>>Pancreatic cancer ;
>>Endometrial cancer ;
>>Glioma ;
>>Prostate cancer ;
>>Melanoma ;
>>Chronic myeloid leukemia ;
>>Acute myeloid leukemia ;
>>Small cell lung cancer ;
>>Non-small cell lung cancer ;
>>Breast cancer ;
>>Hepatocellular carcinoma ;
>>Gastric cancer ;
>>Central carbon metabolism in cancer ;
>>Choline metabolism in cancer ;
>>PD-L1 expression and PD-1 checkpoint pathway in cancer ;
>>Diabetic cardiomyopathy ;
>>Lipid and atherosclerosis ;
>>Fluid shear stress and atherosclerosis